INVO Fertility, Inc. (IVF): Nasdaq/NYSE listing notice — INVO Bioscience receives Nasdaq delisting notice for low stockholders' equity

INVO Fertility, Inc.

Stockholders' equity of $1,287,224 as of Sept 30, 2022, below Nasdaq's $2.5M minimum requirement.
Must submit a compliance plan to Nasdaq by January 7, 2023 (45 days from November 23, 2022).
If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
Failure to regain compliance could result in delisting, with right to appeal to Nasdaq Hearings Panel.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

(the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,287,224, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-033824

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.